Related Experiment Video
Updated: May 11, 2026
11:44
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
[Changes of protein expression in HepG2 cells with CDK2 RNA interference]
Jin Shang1, Zhenyu Wang, Junzao Li
1Department of Dermatology, Frist Affiliated Hospital, Baotou Medical College, Baotou Public Security Bureau, China. shangjin.8299@yahoo.com.cn
Summary
CDK2 siRNA significantly inhibited hepatocellular carcinoma HepG2 cell proliferation and CDK2 mRNA expression. Four novel proteins were identified as not expressed in treated cells, impacting cell biology.
Area of Science:
- Molecular Biology
- Cancer Research
- Biochemistry
Context:
- Hepatocellular carcinoma (HCC) is a significant global health concern.
- Cyclin-dependent kinase 2 (CDK2) plays a crucial role in cell cycle regulation and cancer progression.
- Targeting CDK2 is a potential therapeutic strategy for HCC.
Purpose:
- To investigate the effects of stable transfection of CDK2 siRNA on biological activities and nuclear proteins of human hepatocellular carcinoma HepG2 cells.
- To assess the impact of CDK2 inhibition on cell proliferation, cell cycle, and protein expression profiles.
Summary:
- Stable transfection of CDK2 siRNA in HepG2 cells significantly inhibited cell proliferation and reduced CDK2 mRNA expression.
- Two-dimensional electrophoresis-mass spectrometry identified four proteins (ribosomal protein S12, β-actin, zinc finger 276, and chaperonin 10 related protein) that were not expressed in CDK2 siRNA-treated cells.
- Western blotting confirmed the differential expression of these proteins.
Impact:
- CDK2 siRNA demonstrates potential as a therapeutic agent for hepatocellular carcinoma by suppressing tumor growth.
- Identification of novel proteins affected by CDK2 inhibition provides insights into HCC pathogenesis.
- This study contributes to understanding the molecular mechanisms underlying HCC and informs the development of targeted therapies.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:39Positive Regulator Molecules
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
01:23Negative Regulator Molecules
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.